secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regen BioPharma Inc (RGBP)
CIK:        0001589150
Form:       8-K
Filed at:   2022-09-20T23:59:59+00:00
Accession:  0001607062-22-000586
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regen BioPharma files patent on RNA/DNA dual checkpoint-gene silencing immunotherapy
--------------------------------------------------------------------------------

- Filed provisional patent 'Dual Checkpoint Inhibitor Aptamer Based Therapeutics' targeting NR2F6 and Survivin gene silencing combined with PD-1 checkpoint inhibition.
- Company claims it is the first combination of immunotherapy and gene silencing in a single drug.
- Technology uses aptamers (short DNA/RNA) to deliver gene-silencing sequences while inhibiting traditional immune checkpoints like PD-1.
- CEO David Koos believes platform will yield numerous potent therapeutic candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/0001607062-22-000586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1589150/000160706222000586/rgbp091922form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-22-000586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer